Journal
BRITISH JOURNAL OF CANCER
Volume 126, Issue 1, Pages 1-3Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-021-01618-0
Keywords
-
Categories
Funding
- French Government (Agence Nationale de Recherche, ANR) [ANR-11-LABX-0028-01, IDEX UCAJedi ANR-15-IDEX-01, R19162DD]
- CANC'AIR Genexposomic project, Canceropole PACA
- DREAL PACA, ARS PACA, Region Sud, INSERM cancer
- INCA Plan Cancer
- Children Medical Safety Research Institute (CMSRI) [R17033DJA]
Ask authors/readers for more resources
The combination of COVID-19 vaccination and immunotherapy by checkpoint inhibitors in cancer patients may intensify immunological stimulation with potential reciprocal benefits, but caution should be exercised due to possible adverse events that can arise in each treatment modality.
The combination of COVID-19 vaccination with immunotherapy by checkpoint inhibitors in cancer patients could intensify immunological stimulation with potential reciprocal benefits. Here, we examine more closely the possible adverse events that can arise in each treatment modality. Our conclusion is that caution should be exercised when combining both treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
